WELLESLEY HILLS, Mass., Aug. 20 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee of the assets of Spherics, Inc. ("Spherics") for the benefit of creditors, announced today that all pharmaceutical intellectual property will be sold at a sealed bid auction on October 10, 2008.
One of the pieces of intellectual property for sale is its lead product, SRx-502, Topiramate Extended Release, a once-a-day version of a branded drug that currently has more than $2 billion in U.S. sales despite twice daily dosing and an unfavorable AE profile. A clear clinical pathway for SRx-502 has been defined by the MHRA for a regulatory submission. A successful bidder may make a new drug submission in 4Q 2009 with the remaining total cost to bring to market expected to cost $7 million.
Persons interested in bidding must sign a Confidentiality Agreement ("CA") obtained from Finn's office -- firstname.lastname@example.org or 781-237-8840. They will then receive a bid package and access to the Spherics electronic data room.
Spherics has built a strong intellectual property position around its drug delivery technologies and products. The Company has a broad range of issued US and international patents through exclusive licenses from Brown University. These patents cover polyanhydride-based bioadhesive polymers and PIN. In addition to these issued patents, Spherics has filed numerous applications covering compositions of matters of its proprietary polymers (SPHEROMERS), novel oral delivery systems (including BIOGIT, BIOROD and PIN), manufacturing methods, methods of use, formulations and product compositions.
About Joseph F. Finn, Jr., C.P.A.
Joseph F. Finn, Jr., is the founding partner of the firm, Finn, Warnke
& Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts.
He works primarily in the area of management consulting for distressed
enterprises, bankruptcy acco
|SOURCE Spherics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved